L718 and/or l792 mutant treatment-resistant egfr inhibitor
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorsShinichi HASAKO, Takao UNO
Life of this patent
Estimating the term…
Abstract
The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropy-rimido[5,4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.
Claims12
A method for predicting therapeutic effects of chemotherapy using an antitumor agent comprising, as an active ingredient, (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof in a malignant tumor patient,
- the method comprising:
- (1) detecting the presence or absence of a mutation of EGFR gene contained in a biological sample obtained from the patient;
- and
- (2) predicting based on results of the detecting in (1) that the chemotherapy is highly likely to exhibit sufficient therapeutic effects with respect to the patient when the results of the detection in (1) show that the EGFR gene has at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue.
A method for treating a malignant tumor patient, the method comprising:
- (1) detecting the presence or absence of a mutation of EGFR gene contained in a biological sample obtained from the malignant tumor patient;
- (2) predicting based on results of the detecting in (1) that chemotherapy using an antitumor agent comprising, as an active ingredient, (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof is highly likely to exhibit sufficient therapeutic effects with respect to the malignant tumor patient when the results of the detection in (1) show that the EGFR gene has at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue;
- and
- (3) administering (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof to a malignant tumor patient who has been predicted highly likely to sufficiently respond to the chemotherapy using an antitumor agent comprising, as an active ingredient, (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof, in the predicting (2).
Dependencies are inferred from the claim text.